8-K: Theriva Biologics Q1 2026 Update: FDA Alignment on PDAC Trial

Theriva Biologics reported Q1 2026 results, highlighting FDA alignment on a Phase 3 trial for VCN-01 in metastatic pancreatic cancer and progress in retinoblastoma treatment.

Summary

• Theriva Biologics reported financial results for the first quarter ended March 31, 2026.
• The company received FDA alignment on the design of a pivotal Phase 3 clinical trial for VCN-01 in combination with standard-of-care chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC).
• Additional data from the VIRAGE Phase 2b trial suggests VCN-01 may have an immune-mediated mechanism of action, potentially leading to improved outcomes.
• VCN-01 is also being explored for retinoblastoma treatment, with compassionate use cases providing initial data.
• The company had $14.4 million in cash and cash equivalents as of March 31, 2026, with a projected cash runway into Q1 2027.
• General and administrative expenses increased by 43% to $2.1 million, primarily due to higher legal fees, investor relations, and salary costs.
• Research and development expenses decreased significantly by 88% to $355,000, mainly due to the completion of the VIRAGE Phase 2b trial.
• Net loss for the quarter was $2.0 million, or $(0.05) per share.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with significant regulatory progress on the lead candidate and a clear cash runway, balanced by increased operating expenses and the inherent risks of clinical development.

Positives

• Alignment with the FDA on the design of a pivotal Phase 3 clinical trial for VCN-01 in metastatic PDAC, consistent with EMA feedback.
• Additional data from the VIRAGE Phase 2b trial suggests VCN-01 may have an immune-mediated mechanism of action, potentially leading to improved and more durable tumor responses and longer survival.
• VCN-01 is being advanced for retinoblastoma treatment, with compassionate use cases providing initial feasibility and tolerability data.
• Cash and cash equivalents increased to $14.4 million as of March 31, 2026, providing a cash runway into Q1 2027.
• The Phase 3 trial for PDAC will include repeat dosing and an adaptive design to optimize timelines and outcomes.
• Improved overall survival was observed in VCN-01 treated patients across multiple subgroups, including those with liver metastases.

Negatives

• General and administrative expenses increased by 43% to $2.1 million for Q1 2026 compared to Q1 2025, driven by higher legal fees, investor relations costs, and salary costs.
• Net loss for the quarter was $2.0 million, compared to $4.3 million in the prior year period.
• Weighted average shares outstanding increased significantly from approximately 2.8 million in Q1 2025 to 41.1 million in Q1 2026, impacting per-share metrics.
• The initiation of the third cohort for the SYN-004 (ribaxamase) trial is dependent on additional funding.

Risks

• The company's ability to finalize the protocol for the proposed pivotal Phase 3 trial for VCN-01 in metastatic PDAC and file a BLA.
• The company's ability to obtain development funding and/or partnerships.
• The commencement of the planned Phase 3 study in patients with metastatic PDAC remains subject to sufficient financing.
• The company's ability to raise capital and/or enter into strategic alternatives, which may include business combinations, mergers, or reverse mergers.
• The ability to reach clinical milestones when anticipated, including patient enrollment.
• Generating clinical data that establishes VCN-01 may improve patient outcomes in metastatic PDAC patients.
• Obtaining regulatory approval for commercialization of product candidates or complying with ongoing regulatory requirements.
• Developments by competitors that render products obsolete or non-competitive.

Future Outlook

The company anticipates R&D expenses to decrease in the near future until additional clinical trials commence. Key future activities include focusing on regulatory interactions for a pivotal VCN-01 trial in retinoblastoma, VCN-01 manufacturing scale-up, a Phase 2a study in metastatic PDAC patients evaluating VCN-01 dosing frequency, and limited preclinical studies. The first patient enrollment for a retinoblastoma Phase 2/3 trial is expected in December 2026, with rolling BLA submissions targeted for 2029.

Management Comments

• "The first quarter of 2026 was marked by encouraging regulatory progress. We were pleased to receive the minutes from our end-of-Phase 2 meeting with the FDA and align on the major elements of our proposed pivotal Phase 3 trial to evaluate VCN-01 with gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy in patients with metastatic PDAC."
• "We believe that repeated macrocycle dosing of VCN-01 and chemotherapy may enhance this immune action, providing increased and more durable tumor responses and longer survival."
• "As we finalize the pivotal Phase 3 study protocol, we plan to generate feasibility data for the intended Phase 3 macrocycle dosing regimen, by conducting a small study in metastatic PDAC patients administering more frequent VCN-01 doses for a longer period."
• "We believe that intravitreal coadministration of VCN-01 with topotecan may provide a new treatment option for children with refractory retinoblastoma and vitreous seeds, which remains an unmet medical need in patients with this rare disease."
• "We expect that outcomes from these compassionate use patients will provide valuable information on the feasibility and tolerability of this combination for use in a potential Phase 2/3 clinical trial."

Industry Context

StockSavvy.ai notes that Theriva Biologics' progress in aligning with the FDA on a Phase 3 trial for VCN-01 in metastatic PDAC is a significant step in a highly competitive and challenging oncology landscape. The company's focus on oncolytic viruses and combination therapies reflects broader industry trends aimed at improving treatment efficacy and overcoming resistance mechanisms in difficult-to-treat cancers.

Comparison to Industry Standards

• The VIRAGE Phase 2b trial met its primary endpoints for overall survival (OS), progression-free survival (PFS), and duration of response (DoR) compared to standard-of-care chemotherapy alone, which is a positive outcome in the context of metastatic PDAC, a disease with historically poor prognosis.
• The observed improvements in OS and PFS in patients receiving two doses of VCN-01 suggest a potential benefit from repeat dosing, a strategy being explored by other companies in the oncolytic virus space to enhance therapeutic effect.
• The company's cash runway into Q1 2027 is a critical factor for a clinical-stage biotech company, as it allows for continued development activities while seeking further funding or partnerships, a common challenge in the industry.

Stakeholder Impact

• Shareholders: The progress in clinical trials and regulatory alignment could positively impact future share value, while increased G&A expenses and the need for future funding present risks.
• Employees: Continued R&D activities and potential future trials may lead to job security and growth opportunities.
• Creditors: The company's cash position and runway are important for its ability to meet its financial obligations.

Next Steps

• Finalize the pivotal Phase 3 study protocol for VCN-01 in metastatic PDAC.
• Generate feasibility data for the intended Phase 3 macrocycle dosing regimen in metastatic PDAC patients.
• Commence a dosing feasibility study in Spain in the second half of 2026.
• Continue discussions to design a Phase 2/3 clinical trial protocol for VCN-01 plus topotecan in retinoblastoma patients.
• Enroll the first patient in a retinoblastoma Phase 2/3 clinical trial in December 2026.
• Scale up VCN-01 manufacturing.
• Commence a proposed Phase 2a study in metastatic PDAC patients evaluating VCN-01 dosing frequency.
• Continue limited preclinical studies supporting VCN-01 and VCN-12.

Key Dates

Recommendation

The company has made significant progress with FDA alignment on a Phase 3 trial for VCN-01, which is a positive development. However, the path to approval is long and fraught with clinical and financial risks. The current cash position provides a runway into early 2027, but further capital raises will likely be necessary. Given the potential upside balanced by substantial risks, a 'hold' recommendation is appropriate for seasoned investors who understand the biotech sector's inherent volatility.

Keywords

Theriva Biologics, VCN-01, Pancreatic Cancer, Metastatic PDAC, Retinoblastoma, Clinical Trials, FDA, Oncolytic Virus